Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 469 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TMZ Clear all
Terminated Phase 2Phase 3 Interventional

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

NCT02414165
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
Toca 511, Toca FC, Lomustine, Temozolomide, Bevacizumab
Biological · Drug
Lead sponsor
Tocagen Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 18, 2026, 5:36 AM EDT
Recruiting Phase 2 Interventional

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

NCT06023641
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 22 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
3
States / cities
Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 18, 2026, 5:36 AM EDT
Terminated Phase 1 Interventional

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

NCT04324840
View directory record Official record
Conditions
Glioblastoma
Interventions
CC-90010, Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

NCT03746080
View directory record Official record
Conditions
Glioblastoma, Glioblastoma With Primitive Neuronal Component, Gliosarcoma, Malignant Glioma, Oligodendroglial Component Present
Interventions
Plerixafor, Temozolomide, Whole-Brain Radiotherapy (WBRT), Radiation Therapy
Drug · Radiation
Lead sponsor
Lawrence D Recht
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 18, 2026, 5:36 AM EDT
Terminated Early Phase 1 Interventional

Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas

NCT02507232
View directory record Official record
Conditions
Glioma
Interventions
NovoTTF-200A, Temozolomide
Device · Drug
Lead sponsor
Santosh Kesari
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Santa Monica, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 18, 2026, 5:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)

NCT00555399
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Glioma
Interventions
Vorinostat, Isotretinoin, Surgical Resection, Temozolomide
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

NCT02511132
View directory record Official record
Conditions
Ewing's Sarcoma
Interventions
Vigil, Temozolomide, Irinotecan, Gemcitabine, Docetaxel
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Little Rock, Arkansas • Miami, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 18, 2026, 5:36 AM EDT
Recruiting Phase 1 Interventional

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

NCT06514898
View directory record Official record
Conditions
Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
Interventions
TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Td vaccine, autologous HSCs, Pembrolizumab
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
4 Years to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

NCT01708174
View directory record Official record
Conditions
Medulloblastoma
Interventions
LDE225, TMZ
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
4 Months and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 18, 2026, 5:36 AM EDT
Recruiting Phase 1Phase 2 Interventional

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

NCT07346157
View directory record Official record
Conditions
Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
Interventions
Liothyronine (L-T3), Bevacizumab, Irinotecan, Temozolomide (TMZ)
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
1 Year to 25 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
San Francisco, California • Washington D.C., District of Columbia • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 18, 2026, 5:36 AM EDT
Terminated Phase 2 Interventional Results available

Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma

NCT00568451
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
carboplatin, paclitaxel, temozolomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 18, 2026, 5:36 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

NCT06478212
View directory record Official record
Conditions
IDH1-mutant Glioma, IDH2-mutant Glioma
Interventions
Vorasidenib, Temozolomide (TMZ)
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
12 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 18, 2026, 5:36 AM EDT
Terminated Phase 2 Interventional

Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome

NCT00004106
View directory record Official record
Conditions
Lymphoma
Interventions
temozolomide
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
3
States / cities
New Haven, Connecticut • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma

NCT00005637
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 18, 2026, 5:36 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

NCT04019327
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
Interventions
Talazoparib, Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

NCT01009788
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation, brca2 Gene Mutation
Interventions
ABT-888, temozolomide
Drug
Lead sponsor
Steven J Isakoff, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 18, 2026, 5:36 AM EDT
Terminated Phase 1 Interventional Results available

Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas

NCT03334305
View directory record Official record
Conditions
Malignant Glioma, High Grade Glioma
Interventions
TTRNA-DC vaccines with GM-CSF, Dose-intensified TMZ, Autologous Hematopoietic Stem cells (HSCs), TTRNA-xALT, Td vaccine
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
3 Years to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 18, 2026, 5:36 AM EDT
Terminated Phase 2 Interventional Results available

Everolimus With and Without Temozolomide in Adult Low Grade Glioma

NCT02023905
View directory record Official record
Conditions
Low Grade Glioma, World Health Organization (WHO) Grade II Astrocytomas, Oligodendrogliomas, Mixed Oligoastrocytomas
Interventions
Everolimus, Temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 1Phase 2 Interventional

Aerosol L9-NC and Temozolomide in Ewing's Sarcoma

NCT00492141
View directory record Official record
Conditions
Ewing's Sarcoma
Interventions
Temozolomide, L9-NC
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

NCT00602576
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
sorafenib tosylate, temozolomide
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 18, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

NCT00005597
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
temozolomide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
106
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 18, 2026, 5:36 AM EDT
Terminated No phase listed Observational Results available

Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide

NCT01452854
View directory record Official record
Conditions
Low Grade Glioma
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 18, 2026, 5:36 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

NCT04216329
View directory record Official record
Conditions
Gliosarcoma, Newly Diagnosed, Glioblastoma
Interventions
Selinexor, Temozolomide, Generic Radiation therapy (RT), Selective serotonin receptor (5-HT3) antagonists, Olanzapine, Salt tablets, Anti-diarrheal
Drug · Radiation · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 18, 2026, 5:36 AM EDT
Terminated Phase 1 Interventional

Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma

NCT02530502
View directory record Official record
Conditions
Adult Glioblastoma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy, Temozolomide
Other · Biological · Radiation + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 18, 2026, 5:36 AM EDT